Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
ClinResearch, GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of asthma demonstrating a reversible obstruction during the last 5 years prior to visit 1.
Patients being prescribed either Symbicort SMART or a free combination of ICS and LABA with SABA as rescue inhaler and being on that treatment for at least 3 month.
A history (documented in the patient's file) of at least one severe asthma exacerbation within 24 months prior to visit 1 but not within the last 30 days prior to Visit 1.
A severe asthma exacerbation is defined as a deterioration of asthma leading to at least one of the following:
* Oral/systemic GCS treatment due to asthma for at least 3 days
* Unscheduled health-care visit due to asthmaHospitalization or emergency room visit because of asthma requiring treatment with oral/systemic GCS
You may not be if
Intake of oral, rectal, or parenteral GCS within 30 days prior to visit
Use of ß-blocking agents
Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to visit 1.
Clareo Health | A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®
